CDMO Partner

한미정밀화학 연구소에서는 국내/해외 CDMO 사업들을 활발하게 진행하고 있습니다. 전임상 단계에서 공정개발, 분석법 개발로 시작하여 임상용 샘플의 GMP 생산까지 연속성 있게 고객사의 니즈에 맞춰서 진행하고 있습니다. 또한 기관에서 제출을 요하는 허가 관련 서류들을 일정에 차질 없이 제공합니다.

HM61713(Olmutinib) HM71224(Poseltinib) HM781-36B(Poziotinib) HM30181A HM95573 Ceftizoxime Rosuvastatin(Rosuzet®)

HM61713(Olmutinib)

  • Hanmi Pharm.
  • Anticancer
  • Ph II
  • Partnership with BI (WW), Zai Lab. (China)
  • HFC manufacture & supply API to BI
  • Rights were returned to Hanmi in 2017

HM71224(LY3337641)

  • Hanmi Pharm.
  • Autoimmune Disease
  • Ph II
  • Licensed to Eli Lilly in 2015
  • HFC supplied API for clinical trial to Eli Lilly
  • Rights were returned to Hanmi in 2019

HM781-36B(Poziotinib)

  • Hanmi Pharm.
  • Anticancer
  • Ph II
  • Partnership with Spectrum
  • HFC supplies a key intermediate to DS CMO for Korea and US markets

HM30181A

  • Hanmi Pharm.
  • PgP Inhibitor for anticancer treatment
  • Commercial
  • HFC supplied API to Athenex

HM95573

  • Hanmi Pharm.
  • Anticancer
  • Ph I
  • Partnership with Genentech
  • HFC provided API for clinical trial to Genentech

Ceftizoxime

  • Astellas
  • Authorized Generic for WW
  • HFC supplies API: One of the top quality API in the world
  • Registered as STD in China

Rosuvastatin(Rosuzet®)

  • MSD
  • Rosuzet® is a dual-action hyperlipidemia drug with Rosuvastatin and Ezetimibe
  • HFC supplies Rosuvastatin to MSD